Novel Retinal Imaging Biomarkers in Early Alzheimer's Disease
Status: | Completed |
---|---|
Conditions: | Alzheimer Disease, Cognitive Studies |
Therapuetic Areas: | Neurology, Psychiatry / Psychology |
Healthy: | No |
Age Range: | 55 - Any |
Updated: | 2/2/2019 |
Start Date: | September 2013 |
End Date: | July 2017 |
The goal of this study is to create new retinal imaging processing software useful for the
development of novel retinal biomarkers of cognitive impairment associated with Alzheimer's
disease (AD).
development of novel retinal biomarkers of cognitive impairment associated with Alzheimer's
disease (AD).
Inclusion Criteria:
1. Result of the standard neuropsychological assessment
2. Are men or postmenopausal women, at least 55 years of age. Postmenopausal women are
defined as women who have had a hysterectomy and/or bilateral oophorectomy; or who
have been amenorrheic for at least 2 years;
3. Fluency in English
4. Participants in mild cognitive impairment (MCI)/prodromal and mild-to-moderate
dementia groups must assign a surrogate for purposes of informed consent and help with
protocol compliance.
Exclusion Criteria:
1. Known or suspected diagnosis of non-AD, associated dementia;
2. Major ophthalmologic comorbidities: Ruptured globe, retinal vascular occlusive
disease, retinal artery occlusion, anterior ischemic optic neuropathy, media
opacification due to corneal abnormalities or cataract that prevent ocular and OCT
examination, glaucoma, wet (neovascular) age-related macular degeneration, history of
intravitreal injections, and macular edema. If two eyes satisfy the inclusion
criteria, both eyes will be included in the study.
We found this trial at
1
site
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
Click here to add this to my saved trials